Recruiting NCT06892379
A Study of HS-20110 in Participants With Advanced Solid Tumors
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: HS-20110 (Phase Ia：Dose escalation ), HS-20110 (Phase Ib:Dose expansion ).
- Who it may be relevant to
- Registry conditions: Solid Tumors. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States, China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 in Participants With Advanced Solid Tumors
Overview
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Interventions
- Drug HS-20110 (Phase Ia：Dose escalation )
HS-20110 for IV infusion of various dose strengths administered in 21 day dosing cycles - Drug HS-20110 (Phase Ib:Dose expansion )
The recommended dose from the dose-escalation stage and other potential doses will be further explored
Primary outcome measures
- Maximum tolerated dose (MTD) or maximum applicable dose (MAD) [Time frame: From day 1 to one months after the last dose in Phase 1a]
- Objective response rate (ORR) as per RECIST v1.1 [Time frame: From screening to 2 months after the last dose]
Secondary outcome measures (4)
- Incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose modification or permanent discontinuation, and specific laboratory abnormalities [Time frame: From the first dose until 90 days after the last dose]
- Objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; overall survival (OS) [Time frame: From screening to up to 3 years after last dose]
- Incidence of anti-HS-20110 antibody (ADA) [Time frame: From the first dose until 90 days after the last dose]
- Drug concentrations of the three components of HS-20110 (including antibody-drug conjugates, total antibody, and payload) [Time frame: From the first dose until 90 days after the last dose]
Eligibility criteria
Inclusion criteria
- Males or females, aged ≥ 18 years.
- Participants with pathologically (histologically or cytologically) confirmed advanced solid tumors.
- Participants have at least 1 target lesion other than CNS lesions according to RECIST 1.1.
Exclusion criteria
- Participants have received or are receiving the following treatment:
- Drug therapy targeting CDH17 (such as small molecule targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, or chimeric antigen receptor T cells).
- Anti-tumor drugs within 14 days prior to the first dose of study treatment; any other IMPs or macromolecular anti-tumor drugs within 28 days prior to the first dose of study treatment.
- Local radiotherapy within 2 weeks prior to the first dose of study treatment; irradiation of more than 30% of bone marrow or extensive radiotherapy within 4 weeks prior to the first dose of study treatment.
- Major surgery within 4 weeks prior to the first dose of study treatment.
- Participants previously treated with drugs that are moderate to strong inhibitors or moderate to strong inducers of cytochrome P450 (CYP) 3A4, strong inhibitors or strong inducers of CYP2D6, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) or drugs with a narrow therapeutic range that are sensitive substrates of P-gp or BCRP within 7 days prior to the first dose of the IMP. Participants who need to receive these drugs during the study period should also be excluded.
- Current use of drugs known to prolong the QT interval or that may cause torsade de pointes. Participants who need to receive these drugs during the study period should also be excluded.
- Live vaccine or live-attenuated vaccine within 28 weeks prior to the first dose.
- Participants who have any Grade ≥ 2 residual toxicity according to Common Terminology Criteria for Adverse Events (CTCAE, version 5.0) from prior therapies (except alopecia and residual neurotoxicity).
- Inadequate bone marrow reserve or hepatic and renal functions.
- Participants with a history of severe allergy (such as anaphylactic shock), previous severe infusion reactions, or allergy to recombinant human or murine proteins.
- Participants who are allergic to any component of HS-20110.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Sequential
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
United States · 7 centers
- BRCR Medical Center INC — Tamarac
- Fort Wayne Medical Oncology and Hematology — Fort Wayne
- Carolina BioOncology Institute — Huntersville
- The University of Texas MD Anderson Cancer Center — Houston
- NEXT Dallas — Irving
- NEXT Oncology — San Antonio
- NEXT Virginia — Fairfax
China · 1 center
- SUN YAT-SEN University Cancer Center — Guangzhou
Identifiers
NCT: NCT06892379 · HS-20110-101